Merck KGaA, GSK Enter Immuno-Oncology Collaboration Valued at Up to $4.23 Billion
05 Febrero 2019 - 6:47AM
Noticias Dow Jones
By Donato Paolo Mancini
Merck KGaA (MRK.XE) and GlaxoSmithKline PLC (GSK.LN) have
entered a collaboration agreement valued at up to 3.7 billion euros
($4.23 billion), the two companies said Tuesday.
The agreement will involve eight high-priority immuno-oncology
clinical development studies currently ongoing or due to commence
in 2019, including studies in non-small cell lung cancer and
biliary tract cancers, Merck said.
Under the terms of the agreement, Germany's Merck will receive
EUR300 million as an upfront payment, and will be eligible for
EUR500 million in further milestone payments triggered by data from
the M7824 lung cancer program. On top of this, a total of up to
EUR2.9 billion will be paid for future approval and commercial
milestones, Merck said.
Write to Donato Paolo Mancini at
donatopaolo.mancini@dowjones.com; @donatopmancini
(END) Dow Jones Newswires
February 05, 2019 07:32 ET (12:32 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
